



March 17, 2025, Monthly Update

Topics:

- 1. Excellent response to Zhittya's email regarding the Washington University fMRI study indicating a 21% increase in blood flow in the brain after FGF-1 treatment.**
- 2. 5-week Report on Neuropathy Medical Research Study**
- 3. Zhittya has 5 patents pending on the medical applications of FGF-1, including: (1) Intranasal Treatment of Parkinson's Disease, (2) Intranasal Treatment of Other Brain Diseases, (3) Intranasal Treatment of Type-2 Diabetes, (4) Inhaled Treatment for Lung Disease and (5) Injection to Treat Neuropathy.**
- 4. NevBio Annual Awards Dinner: Dr. Jacobs won the Man of the Year Award! Presentation on April 2, 2025 at the Durango Hotel in Las Vegas**
- 5. Joe Cortez Show interview and Zhittya launching its own**

Medical Information Show.

6. Zhittya's Outreach program to doctors, clinics, and FGF-1 believers— some of our successfully recovering Parkinson's disease patients.

#1) Wonderful Response to our email on the fMRI scan showing a 21% increase in blood flow in the brain.

The Zhittya Monthly Update, I believe, is read by over 100,000 people. A few weeks ago, we sent out a short 3-page message to our followers just showing the results of the first “functional MRI” measuring the blood flow in one of our Parkinson's disease patients. The first fMRI scan was taken before dosing the patient with FGF-1 in the British Virgin Islands. The second scan was taken six months after dosing with FGF-1. The empirical data from the functional MRI scan showed a 21% increase in blood flow in his brain. To our knowledge and to everyone else we have talked to, this is the first reported therapeutically induced increase in blood flow in the brain. We had an excellent response from many, many people. Our theory that insufficient blood flow in the brain causes Parkinson's disease is not well accepted by the medical professionals. Many of them challenge our results that we are reversing Parkinson's disease. They say: “So what, you grew blood vessels and increased blood flow in the brain?” To my complete surprise, about 80% of the respondents to our email were inquiries about our medicine to enhance recovery from a stroke. While few medical professionals accept our premise that lack of blood flow in the brain causes Parkinson's disease, everyone knows a lack of blood flow in the brain causes stroke. We received inquiries from medical doctors, clinics, and people

who were recovering from a stroke or had a loved one struggling with a stroke disability. We had inquiries from Japan, Germany, the Arab world, and all across the United States.

The World Health Organization reports that stroke is the second leading cause of death in the world. The WHO states that 1 out of 4 people will suffer a serious stroke in their life. The Stroke Foundation reports 15 million people are affected by strokes every year worldwide. They also report in the United States about 800,000 strokes occur every year. Sadly, they report that of those 800,000 people having a stroke, about 140,000 die. Equally sad, is that around 650,000 of these people will live with a stroke disability for between 5 and 15 years. If you take the average between 5 and 15 years, as being 10 years; then around 6 million Americans are living with a stroke-induced disability. Stroke sufferers are told by the medical establishment that their degree of recovery is of a limited nature and occurs naturally and there is nothing they can do about it. Now that Zhittya has shown FGF-1 does, in fact, enhance blood flow in the brain, doctors, clinics and patients are reaching out to Zhittya about whether we can do something to enhance recovery from a stroke. Our answer is simple: we have dosed 5 stroke victims so far and according to them, their recovery has been wonderful, and even their doctors are shocked by their improvements.

What is interesting is that an estimated 1 million Americans have Parkinson's disease. About 80% of the over 200 Parkinson's disease sufferers we have treated are Americans. That would represent around 160 Americans. That would mean 0.016% of American Parkinson's disease sufferers have tried our treatment. If 6 million Americans are living with stroke disabilities and 4 of our test subjects are Americans then that is 0.0006% of one percent of those sufferers have tried our

medicine to enhance their recovery. Seems we have not even scratched the surface of that potential medical need.

Given the overwhelming interest regarding Zhittya's treatment to enhance recovery from a serious stroke, Dr. Jack Jacobs is preparing a new White Paper on **"Enhanced Stroke Recovery using FGF-1"**. We have excellent data, fMRI images and more and that new paper should be ready by the first of April. I believe medical doctors know insufficient blood flow causes stroke disabilities and that they are now becoming aware Zhittya has a treatment for them. Our 5 stroke test subjects are evidence something good is happening.

#2) 5-week report on our Neuropathy Medical Research Study

As you recall a person with severe neuropathy pain in his feet had FGF-1 injected into one of his feet about 5 weeks ago. We believe from what we learned in the heart studies that the process of growing new blood vessels and enhancing the neurons in the foot should take 6 to 12 weeks. At 5 weeks, the patient has reported the pain in his treated foot is less by over 80% (a guess by him). A good start.

Neuropathy is reported to affect 20 to 30 million Americans. Neuropathy is generally accepted to be caused by insufficient blood flow in the feet (or other areas) leading to nerve pain, due to lack of nourishment and oxygen to the neurons. FGF-1 injected into the heart grew new blood vessels, reestablished blood flow to heart muscle cells and enhanced heart function and reduced cardiac pain in about 3 months. I am looking forward to the 3-month data on our neuropathy patient.

#3) Zhittya has 5 patents pending to secure our proprietary business

Zhittya is a for-profit business. The management of Zhittya has expended over \$180 million dollars and 27 years of our lives advancing FGF-1 to treat heart disease, brain disorders, diabetes, lungs, legs, feet and more. There has not been one report of a serious adverse event in 40 years of research on FGF-1. Besides my money, we have other investors who seek a reward for their investments, a profit. I strongly believe they should earn a sweet reward for helping us change the world of healthcare and perhaps save millions of people from death and suffering. One major concern people have for us is when we prove our medicine works; how do we protect our development from other competitors? One part of the answer is any competitor would need seven years to get to where we are now. You cannot do a one-year study in less than a year. One nice thing about Big Pharma is I will guess a one-year study would take them 5 years; they are very bureaucratic and slow.

The second way is to have patents which bar possible competitors for around 18 years. Zhittya has five (5) patents pending with the US Patent Office to protect our discovery.

Patent #1: Intranasal FGF-1 for Parkinson's disease

I believe in the USA about a million people have Parkinson's disease, and worldwide the number may be 20 million. The estimated annual occurrence in the USA is between 60,000 and 100,000 people. So, the biggest business opportunity is treating the backlog of sufferers: ~1 million people. I believe after FDA approval, that would take us around 4 to 5 years to clear out all the backlog of sufferers. Then we would treat only the annual occurrence for the remainder of the life of the patents.

Patent #2: Intranasal FGF-1 for neurodegenerative diseases of the brain

I believe other neurodegenerative diseases such as Alzheimer's, dementia, traumatic brain injuries (CTE, ALS, PTSD, etc.) and multiple sclerosis and more are measured in the many tens of millions of people. An 18-year monopoly would be nice, since I believe even 18 years from now when the patents expire, we will still be studying new applications for FGF-1 in the brain.

Patent #3: Intranasal FGF-1 for the treatment of type-2 diabetes

It is reported that 38 million Americans have type-2 diabetes. We have reversed it in ten out of ten patients. I believe in 2025 we will conduct a dedicated Medical Research study to reverse type-2 diabetes. We do not know how long the reversal will last: 6-months, 6-years, or for life? What we do know is getting rid of type-2 diabetes would be a good thing. Imagine 20 years from now people do not remember what type-2 diabetes was, like today we do not worry or think about polio.

Patent #4: Inhaled FGF-1 for lung damage

Damage to the respiratory system is the 4th leading cause of death and a major cause of suffering. We believe that FGF-1 could be used to treat individuals who suffer from scarring or damage in their lungs by using an inhaler to grow new blood vessels in the lungs of those patients. We believe that this could be an effective treatment to reverse lung damage and lung scarring to potentially treat the common symptoms of severe lung damage.

Patent #5: Injection of FGF-1 into tissue to reverse neuropathy

It is reported that 20 to 30 million Americans have neuropathy. Sufferers of neuropathy are told there is no treatment. If FGF-1 can reverse that disease, I believe it is a good thing.

According to the London School of Economics, it takes 18 years and \$1-2 billion dollars to get a drug approved through the US FDA. On our list we have heart disease, Parkinson's disease, type-2 diabetes, neuropathy, strokes, dementia, and more. If each of those all cost 2 billion US Dollars, it is a big sum of money. So far, Zhittya has accomplished things at 1/10th the cost that Big Pharma spends, and we move 5 times faster, in my opinion. Even with that, we will still need lots of money. Some money should come from the profit from our business activities; however, some will come from shares being publicly traded on the stock exchange. Our existing investors and our future new investors deserve an outstanding reward for funding these medical breakthroughs to treat tens of millions of people. These patents we are working upon should greatly enhance the value of our efforts, so our investors are well rewarded for their involvement.

#4) NevBio Annual Awards Dinner Dr. Jack Jacobs recipient

It is with the greatest pride that I get to see Dr. Jacobs recognized for his over 40 years of dedicated efforts in research, commercialization, and solving impossible problems. Below is a copy of an advertisement we placed in the Sunday edition of the Las Vegas Review Journal, the largest newspaper in southern Nevada. The banquet room holds 300 seats for dinner and at last count, over 260 were taken with two weeks to go. We have government officials, politicians, Nevada economic think tanks, business people, patients, two different investment banking firms (who specialize in IPOs), and many investors. Zhittya has maintained a very low profile the last several years, one press release in three years. We decided that talking about what we are going to do (like most biotech companies who only talk) is less valuable than **looking at what we have done!** We have treated 200 Parkinson's disease sufferers and, WOW, look at how they have

improved. We have had success treating the heart, strokes, type-2 diabetes, diabetic foot ulcers (DFU's), neuropathy, and more, and now is the time for Zhittya to come out and tell its story. For millions of people to gain access to our medicines, the drugs will need US FDA approval. In a rational world, I believe our treatment will lower the cost of treating sick people by 75%. A heart patient will not need stents, blood thinners and other medicines. Ten injections into the heart, taking around 30 minutes and after the anesthesia wears off, they can go home. It does not take long to recover from a shot. Interventional cardiologists hate us since they will not earn millions putting metal stents in your inflamed arteries. A neurologist will not earn millions of dollars telling people there is nothing they can do to improve their situation.

This event on April 2nd, in my opinion, will be Zhittya's "Coming Out Party". We are here, we have medical breakthroughs, and we are going to be going to the US FDA with answers and you people to make sure they perform. We are going to seek to modify the Nevada State "Right to Try Law", so people can actually try to improve their lives. Remember, Nevada is not a prosperous state because it has empty sandy deserts, it is because Nevada in 1931 allowed legal gambling. I believe Nevada allowing real "Right to Try" will be a bigger economic and business opportunity than gambling has been. People would fly from all over the world to try and treat their Parkinson's disease, their No Option Heart Condition, their Alzheimer's disease, etc.; rather than wait 18 more years for the USA FDA to get around to it. We will keep you posted!

Here is a copy of the advertisement we placed in the Las Vegas Review Journal

Parkinson's Disease Reversed by Nevada Biotech Company

The above is the title of Presentation to be given:

NevadaBio Annual Awards Dinner April 2, 2025, Durango Hotel

Nevada Bio was founded in 2006 to encourage the economic and scientific development of biotechnology in Nevada via biotech events with scientists, doctors, researchers and political leaders. Join Nevada Bio on April 2, 2025 to award Dr. Jacobs as The Man of the Year for his medical discovery in Parkinson's disease.

Dr. Jack Jacobs, President and CSO of Zhittya Genesis Medicine, and the winner of this year's award, has been a pioneer in regenerative medicine.

Dr. Jacobs originally discovered this molecule in the late 1980s and has since seen his research grow into US FDA clinical trials and pre-clinical studies, having seen results in not only treating Parkinson's Disease, but heart disease, stroke, and more.



Zhittya Genesis Medicine

With Dr. Jacobs as its President, Zhittya Genesis Medicine has made advances in treating diseases caused by using FGF-I to grow new blood vessels, potentially treating heart disease, diabetic foot ulcers, Parkinson's Disease, neuropathy. Zhittya Genesis Medicine is actively recruiting for patients in medical research studies for:

- Parkinson's Disease • Strokes • Neuropathy

We Have Treated Over 200 Patients With Parkinson's Disease
Visit: zgm.care for more information!

Sponsors:

Stavros Anthony- **Lt. Governor of the State of Nevada**
Shelley Berkley- **Mayor of Las Vegas**
John Ensign- **DVM & Former U.S Senator**
Thomas Burns- **Executive Director of the Governor's Office of Economic Development**
John Tsarpalas- **Executive Director of Nevada Policy Research Institute**
Dr. Robert Odell- **Owner of the Neuropathy & Pain Centers of Las Vegas**
Dr. Nabil Sakkab- **Chairman of BiOWish Technologies**
Kevin Prince- **Registered Patent Agent, Quick Patents**
Zhittya Genesis Medicine, Medical Research Studies Management Inc., Roth Capital,
Cross Border Medical Tourism Inc., Foley Law PC, Benjamin Securities,
Monterey & Dr. Jeffrey Brookman, John & Marianne Gibson, Jim Marsh

866-786-0044

Visit nevbio.org for more information!

#5) Joe Cortez Show: Dan Montano

Joe Cortez is one of the most famous boxing referees in the world. He has a 30-minute YouTube show that he has created. I was on a few weeks ago talking about our medicine and here is the link to that show:

<https://youtu.be/PZMQ2RgOAPM>

Another famous boxing referee is Richard Steele. Both Joe and Richard have retired to Las Vegas, a major area for boxing and mixed martial arts (MMA). I believe, between the two of them, they have refereed 60% of all the major title fights in the world over the last 40 years. Both will be at the April 2nd event. They have impressive relationships with the athletes and the regulators of boxing and MMA. One of the biggest issues with those contact sports are head injuries. Mohamed Ali developed Parkinson's disease from the blows to his head. Both men know the effects of head contact sports. Also, I believe two other men who were on the Nevada State Boxing Commission will be with us at the April 2nd event. It would be great to treat a famous boxer with brain issues and enhance his recovery with our FGF-1.

Additionally, Joe showed us how to do a YouTube Show, so we will be starting one soon for Zhitty. Once a week medical breakthrough from Zhitty, we have a lot to talk about.

#6) Zhitty's Out Reach Program

With all the success, we are having on our Medical Research Studies, some of our supporters have taken to giving presentations on our medical breakthroughs to their local groups. One of our biggest supporters has prepared a PowerPoint presentation, and then he reached out to local organizations. Not to Parkinson's disease groups, as they do not like us because they fear losing their Big Pharma

sponsors. He has been invited to several women's groups who have monthly meetings and are looking for interesting speakers. He gave one presentation at a Las Vegas retirement community and had 130 attendees and a great response. Many attendees have loved ones whom they want to share what we have accomplished. It has been a wonderful response, and the groups he has talked to want him to come back and give follow-up presentations on our progress. Many of Zhittya's Lab Rats (a term of endearment) have asked many times, "How can I get the world to know that this is real?". We have had medical doctors who own a clinic, who would like to give presentation in their area to educate people on new medical therapies coming for those diseases that have no present treatment, diseases like Parkinson's disease, dementia, Alzheimer's, neuropathy, severe diabetic foot ulcers, chronic leg ischemia, and more. We have been contacted by clinics in Germany, Japan, the Arab world, and several in the United States in the last month who want to reach out to their community and show people they may have something different for patients, if not today; maybe next year. One MD advertised his presentation: "**Parkinson's Disease is there a treatment that can reverse this disease?**" He had 45 people attend, and he says 10 of those patients have started to use his medical practice since he is (according to one of his new patients) "so far ahead of his original neurologist on new possible treatments for Parkinson's disease". Interestingly, he said most of his new patients had been with neurologists at major medical universities, where the people stated, "It is amazing that the university doctors are so cautious in their ways, they will not even listen about what is new or seem to care about what is possible."

So, to start and spread the word, Zhittya is launching our "Outreach Program."

Test subjects, believers, doctors, and clinics are welcome to join us in this activity to enhance your business, make some money and help people. People with these diseases (that our medicine appears to treat) are tired of being told there is nothing for you to improve. Some of these doctors are using this topic to attract new patients to their practice.

I, personally, will be leading this effort as I need to be hands-on, if we are going to figure out how to make this a success for all. If you would be interested in helping us spread the word, please email me at: Dan333@aol.com

We have happy Parkinson's disease patients from all over the world. Help us tell your story and for clinics let us help you enhance your medical practice.

Vika Montano's Patients' Comments Section: Every month, I receive emails and phone calls from our test subjects. Here I have selected a few of their comments so you can read what those who have joined our Medical Research Studies are reporting to us.

1) Mark is making some progress. It's still slow. PT is helping. It seems like his muscle cramping has decreased and is at a minimum. He doesn't take magnesium for that anymore. His sleep is still interrupted to turn because of discomfort. Hopefully that will subside and he will get much longer stretches of sleep. His chewing and swallowing has improved.

He's able to get himself out of chairs most of the time when he's well rested. We are so appreciative to be included in this study. I haven't found any other recovery options available.

Sue

2) Thank you! I feel good less fatigued, better voice quality except when I'm tired, I still slur my right hand is getting better but my left side is having symptoms I haven't had before. That said hopefully/prayerfully it's as bad as it's going to get and will start getting better (Fine motor coordination and strengthening). Thank you for all you and Dan and your staff have done for us.

Sincerely, Anne-Marie

3) Hi Vika,

This is Mike. Debra is doing much better than she was while at Tortola for Cohort 16. She has improved over the last year. She now gets up and down, brushes her teeth, and bathes by herself. Her drooling has stopped, and her freezing gait is almost gone. She helps me with cooking and laundry. She still has tremors in her right arm and hand, and her right leg still drags some as she walks.

I attribute her improvement to multiple things, the FGF-1 dosing, going to a movement disorder specialist, exercising, and getting a new Parkinson's medicine. Tell Dan & Sam "Hello" for us.

Mike

4) I continue to work half time with plans to cut to 1/4 time in May as I'm approaching 67 this fall. I still enjoy work.

In general my constipation is improved, fatigue is a factor, my hands remain my most significant symptom. Nonetheless I have much to be thankful for. Thanks for all your hard work and thanks to everyone at Zhittya, sat hi to one and all.

Kevin xxxxxxxx MD

5) Mark's new abilities are walking up and down the stairs unassisted, moving away from having his back to a wall, eating bite sized food using a fork, sometimes getting himself to standing from a cross-legged position on the floor, and getting himself off of most chairs by himself including his recliner. His voice is still an issue but there are times when he's feeling stronger when I can understand him better.

He is receiving two PT sessions a week and one OT session a week. It has helped him regain muscle strength since the pneumonia.

Mark does not take meds for anything. He's never been comfortable taking Parkinson's meds.

We haven't noticed any regression since he's started FGF-1 except when he had pneumonia. He's regained what he lost from his illness and is now progressing into new abilities.

Sue xxxxxxxx

6) Hello Vika,

I just wanted to give you an update.

My husband and I were talking the other day and he said "what do you think is the percentage of your improvement" and I said 10%. We then talked about the areas of my improvement and he decided that is more like 20%

Here are the areas.

My handwriting is better

I can smell things better sometimes

My toes do not cramp up as much

I do not stumble or have a missed step in my aerobics class

My walking is a little better

I seldom shout out at night, or have a nightmare.

I thank you, Dan, and Sam, for everything you did for me in the program and for the others. Bless you.

Sincerely, Leslie

7) Dear Vika, My sleep has become deeper and a solid six hours now. I have developed tongue chewing which is annoying, but is controllable with focus. My brain fog is all but gone with having an episode one or two a day.

Cross Border Medical Tourism

Cross Border Medical Tourism services are for those people who want to be considered for Zhittya's future clinical trials or its current Medical Research Studies. Cross Border's focus is to fill all available slots in the Medical Research Studies in the British Virgin Islands and The Bahamas, while we wait for other clinics to come online.

Cross Border is working on filling the available slots for the next BVI Medical Research Studies (intranasal FGF-1 for Parkinson's disease) on the following dates:

Cohort #35: April 7 – 13, 2025

Cohort #36: May 2 – 7, 2025

Cohort #37: June 2 – 7, 2025

I am showing cohorts further out in time since we are filling up faster and have fewer spots open each month.

Please contact Sam Cross at Cross Border Medical if you wish to be considered for the BVI cohorts or slots in The Bahamas. Sam's email address is:

sam.crossbordermedical@gmail.com.

In addition, if you are interested in participating in the brain scan studies which will take place at Washington University in St. Louis, please let Sam know. There are a finite number of slots for the imaging studies. These studies will look at brain blood flow before and after treatment with FGF-1.

Upcoming Events

Freedom Fest 2025

June 11 – 14 in Palm Springs, California

Dr. Jacobs and I will both be presenting at the FreedomFest in June, where normally many elected government officials attend. Last year, they had over 2,500 attendees. At the 2023 Freedom Fest, they hosted Robert Kennedy Jr. as a Keynote Speaker, and we were able to chat with him there.

Dr. Jacobs in his section below will discuss the success with Parkinson's Disease patients and the potential to reverse stroke damage with FGF-1.

I will be speaking on the Main Stage that changing the "Right to Try Law" to something reasonable would accelerate medical innovation and provide a lower barrier to entrepreneurial medical innovators, who do not have access to a billion dollars. I have seen amazing medical discoveries over the last 20 years not advanced because the barrier is 1 to 2 billion dollars is a huge issue. Most of the medicines Big Pharma sells you today were developed 40 to 50 years ago. Imagine without innovative completion we would not have cell phones, smartphones etc. The freedom to compete is what has made America great and its citizens prosperous!

Dr. Jack Jacobs

As Dan mentioned above, two weeks ago, we sent out a short, 3-page message showing the results of the first “functional MRI” scan measuring blood flow in the brain of one of our Parkinson’s disease patients. The MRI scan showed a 21% increase in blood flow. To our knowledge, this was the first reported increase in brain blood flow induced by a therapeutic. To our surprise, 80% of people responding to that email had questions on whether our medicine could enhance recovery from a stroke. Because of that, I would like to review the information we have to date on using FGF-1 to reverse stroke damage.


A healthy and intact vascular system in the brain is critical for normal human functioning, both motor and cognitive. Any disruption in the brain’s blood perfusion system can lead to dire consequences, as the brain neurons are deprived of glucose and oxygen and begin to quickly atrophy and die. A number of medical conditions are characterized by a disruption of blood flow to the brain, but some conditions, such as stroke, have long been known to be directly tied to a breakdown in the brain’s vasculature system.

Stroke is the 5th leading cause of death in the US, with one person dying every 4 minutes as a result. Approximately 800,000 people have a stroke each year; about one every 40 seconds.

Previous work in animal models of stroke has demonstrated that FGF-1 can diminish the extent of brain damage in these animals. The mechanism by which this transient intervention works in animal models is not entirely clear, but the efficacy of FGF-1 could be related to the prevention of apoptosis (programmed cellular death) of stressed neurons. It should also be noted, that unlike most proteins, FGF-1 has been shown to cross the blood-brain barrier and may be one


reason FGF-1 has shown efficacy in stroke models when delivered intravenously. FGF-1 was tested in an animal model of stroke, where a stroke is experimentally induced by temporarily occluding the cerebral artery. As shown in the figure below, FGF-1 had excellent activity in this model, reducing stroke infarct volumes significantly.

Effect of FGF-1 treatment in an animal model of acute stroke. Sectioning through the brain followed by subsequent staining of the brain tissue allowed a visualization of the stroke infarct. The infarct area appears as a white area (A-F) and the effect of FGF-1 in reducing infarct volume (G-L) is readily apparent.



FGF-1 can also stimulate the growth of new brain tissue in animals that are recovering from a stroke. As shown in the figure below, FGF-1 stimulated the growth of new brain tissue over 4 weeks in an animal model of stroke recovery.


Stimulation by FGF of the growth of new brain tissue over 4 weeks in an animal stroke model. Arrowheads point to an area of the brain that has been healed by FGF-1 (Panel C). Panel A is placebo treated and Panel B is a low dose of FGF.




In a study commissioned by Zhittya, it was demonstrated that FGF-1 could be successfully delivered to the brain via the intranasal route. In fact, as demonstrated in the figure below, FGF-1 was widely distributed throughout the entire brain after intranasal delivery. Additionally, almost twice the amount of FGF-1 was delivered to various regions of the brain when comparing intravenous to intranasal delivery.

Concentration of FGF-1 in Brain Tissues 30 min After Intranasal Administration.

Key: IN no hep = intranasal FGF-1 without added heparin; IN hep = intranasal FGF-1 with heparin; IV hep = intravenous FGF-1 with heparin



In previous studies with a Parkinson's disease patient, we had imaged the flow of blood in the brain before and 6 months after treatment with FGF-1. The small areas outlined in white represent the location of the substantia nigra region of **red is less blood flow, yellow is more blood flow** to the brain.



With these very promising results in animals, we initiated studies in humans, intranasally administering FGF-1 to patients who had suffered a stroke. With five stroke patients treated to date, we are seeing a very nice improvement so far in terms of patient motor skills and cognitive abilities.

Conclusion by Dan Montano

This Update is very full, as we are advancing on many tasks at the same time. Zhittya has many wonderful projects working to advance what, I believe, is the greatest medical breakthrough of the last 100 years. It is reported that 65% of all adults die from a disease which is caused by the lack of blood flow to a tissue or an organ. I believe FGF-1 with its ability to trigger new blood vessels growth could defer death and suffering for 90% of those people. Zhittya has advanced below the radar for decades. I believe over the next 6 months, Zhittya must go on a "Full Court Press" to accomplish many important treatments. We have great data; however, our barrier is the USA FDA. I do not want to be deferred another ten years waiting for the FDA to respond to a cure for type-2 diabetes, because of all

the money they get from Big Pharma dealing with the symptoms; not the cause of the disease. I believe we have a “Window of Opportunity” to advance our medicines and get some approved sooner now that Washington DC is demanding “Common Sense” regulations. I believe our Window of Opportunity is **46 months**. We need to make progress when we have the wind to our back. Zhittya has been quietly advancing with obtaining great human data. Now we must now “Charge into this Battle and seek victory!”

This FGF-1 molecule was discovered over 40 years ago. It has been used by us and others in medical research and has been safe with amazing outcomes. From deferring death from heart disease, to treating brain disorders, to diabetes, to neuropathy, and more, yet it has not reached the hundreds of millions of people who could have benefited from it had it been approved in the 1990s. Of the 17 million people who die of heart disease every year, I believe FGF-1 could have prevented the deaths of 85% of those people. From simple math, I will guess 14 million people per year could have been saved if it had been approved in 1998. Today, 2025, it is 27 years later, and at 14 million people times 27 years, it is 370 million people whose lives we could have extended, except for rules of the FDA to protect those people from what, Life? They died because this medicine was trapped in a Byzantine Bureaucracy of delay, delay, delay.

We have **46 months** to accomplish what has not been accomplished in 46 years, getting FGF-1 to sick humans.

Now, people! Now! We must rally and get the FDA to use Common Sense, making sick people suffer and die is not right.

I pray we all succeed!

Bless you all!

Dan Montano, CEO

Zhittya Genesis Medicine

1120 North Town Center Drive, Suite #270,

Las Vegas, Nevada 89144

United States of America

zgm.care